Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)

**Product type:** Human Prescription Drug

**Active ingredient:** ATEZOLIZUMAB; HYALURONIDASE (HUMAN RECOMBINANT)

**Strength:** 1875; 30000 mg/15mL; U/15mL

**Dosage form:** Injection

**Route:** Subcutaneous

**Labeler:** Genentech, Inc.

**Marketing category:** BLA (BLA761347)

**Pharmacologic class:** Antibodies [CS], Antibodies, Monoclonal [CS], Antibodies, Monoclonal, Humanized [CS], Endoglycosidase [EPC], Glycoside Hydrolases [CS], Programmed Death Receptor-1 Blocking Antibody [EPC], Programmed Death Receptor-1-directed Antibody Interactions [MoA]